If it does not touch GABA, why keep the name gabapentin?
Is a Neurontin 600 mg tablet cheap to order as a generic?
The price ping arrives before the history. People type cheap Neurontin 600 mg, generic gabapentin, order online, and expect a brand story. The tablet they mean is a 1998 scored film-coat, not a 1970s sketch.
A US Neurontin 600 mg tablet is white, elliptical, scored, and stamped NT 16. The Food and Drug Administration cleared that strength on 9 October 1998 under NDA 020882, five years after the first capsule licence. Capsules stay at 100, 300, and 400 mg. The 600 and 800 mg units are tablets. If a cart shows a 600 mg capsule, the listing is already noise.
Generic gabapentin 600 mg is usually cheap because the patent died years ago. Cheap is not a clinical clearance. The scored 600 mg tablet can be split, and unused halves should be taken as the next dose or discarded after 28 days, per the current label. That is a pharmacy handling note, not a reason to start at 600 mg on day one. The labelled PHN climb still opens at 300 mg. Day 2 is already 600 mg a day, split. The full labelled strengths and holds sit in the Neurontin 600 mg monograph.
Ordering a 600 mg tablet online without a prescription is not a Parke-Davis story and not a desk recommendation. This site is a journal, not a cart. The history below explains why that particular milligram became the unit people still search, and why the brand name Neurontin still sits on a Pfizer-era label even when the bottle in the bag says gabapentin.
The GABA name was the first false ping
Chemists in the 1970s wanted a GABA analogue that could cross into brain. Plain GABA does not. They fused a cyclohexane ring onto the amino acid and named the product after the parent they hoped it would impersonate. The bet failed in a useful way. Gabapentin does not bind GABA-A or GABA-B, does not become GABA, and does not explain its effect by blocking GABA breakdown.
Years later the lock was named: the alpha-2-delta subunit on voltage-gated calcium channels at nerve terminals. Occupy that subunit and fewer channels reach the membrane. Less calcium enters when the terminal fires. Less glutamate and substance P leave. Over-firing quiets. That is a calcium-channel story wearing a GABA badge. Residents who reason from the badge write the wrong consult.
The name stuck because the drug was already selling when the mechanism caught up. Nobody renames a marketed anticonvulsant for the sake of honesty. So the first flag on any Neurontin file is still the same: ignore the etymology, keep the subunit.
Ann Arbor, Parke-Davis, and a quiet European start
Parke-Davis, then the drug arm of Warner-Lambert, ran the gabapentin bench in Ann Arbor, Michigan. Later FDA letters still list Plymouth Road. That address is not folklore.
Add-on anticonvulsants rarely launch with a parade. Neurontin reached European patients before the US licence, and the early forecast was modest: bolt it onto an existing seizure drug when partial seizures still broke through. Nobody in Ann Arbor was drawing a blockbuster poster. The molecule looked like a supporting actor.
That quiet start matters because it explains the later shock. A drug designed as adjunctive therapy does not need a huge monotherapy story. It needs a clean interaction profile and a tolerable climb. Gabapentin is not metabolised by the liver and does not induce or inhibit the CYP enzymes other anticonvulsants live on. That cleanliness is why epileptologists could add it without rebuilding the whole stack. It is also why, later, pain clinics could add it without a drug-interaction lecture. Clean is not the same as proven for every complaint.
December 1993: an add-on licence, not a solo career
The US Food and Drug Administration approved Neurontin in December 1993 as adjunctive therapy for partial (focal) seizures in adults. Adjunctive is the load-bearing word. It was cleared to sit beside another antiseizure drug, not to replace one. The Department of Justice later repeated that narrow first licence when it described the marketing case. A supporting actor got a supporting licence.
The current label also covers adjunctive partial-onset seizures, with or without secondary generalisation, in patients 3 years and older. That paediatric line is a later widening, not the 1993 opening. Treating the first approval as a general epilepsy stamp is how the noise starts. Monotherapy for new-onset epilepsy was never the original ping.
If you want the regulator's own short list rather than a forum recap, the approved-use language is on the FDA site. It is shorter than most 600 mg review threads.
1998: the 600 mg scored tablet becomes a unit
1970s
A cyclohexane-GABA hybrid is drawn so a calming amino acid can enter brain. The hybrid is named gabapentin.
Dec 1993
FDA clears Neurontin as add-on therapy for partial seizures in adults.
9 Oct 1998
The 600 mg and 800 mg scored film-coated tablets are approved (NDA 020882).
Jun 2000
Pfizer acquires Warner-Lambert. Neurontin and the off-label volume travel with the deal.
2002
Postherpetic neuralgia becomes the first approved pain indication.
13 May 2004
Warner-Lambert resolves criminal and civil Neurontin promotion charges for more than $430 million.
6 Apr 2011
Gabapentin enacarbil (Horizant) is approved for moderate-to-severe primary restless legs. PHN for that prodrug follows in 2012.
Capsules launched first. The 600 mg film-coated tablet arrived on 9 October 1998 with an 800 mg sibling. That is the milligram this journal locks for SERP on this domain, because it is a real labelled tablet, not a made-up strength. People still ask for 'the 600' the way they ask for a 20 mg statin: as a familiar unit, not as a diagnosis.
For epilepsy in patients 12 and older, the labelled start is 300 mg three times daily, and the climb may reach 600 mg three times daily - 1800 mg a day. For postherpetic neuralgia the usual target is also 1800 mg a day, which is 600 mg three times daily after a slower first-week ladder. So 600 mg is both a tablet and, later, a single dose on a three-times-daily grid. Those are not the same instruction. Mixing them is how a cheap start becomes a hard first day.
The handling footnote is small and often skipped. If a scored 600 mg tablet is split, take the leftover half as the next dose. Do not pocket halves for a month. The label's 28-day discard is the flag.
Pfizer inherits the brand, then a pain flag lands
Pfizer bought Warner-Lambert in June 2000. The prize most analysts named was atorvastatin. Neurontin rode along. By then a large share of Neurontin prescriptions already sat outside the 1993 seizure add-on. Pfizer inherited the revenue and the liability in the same closing binder.
In 2002 the label gained postherpetic neuralgia in adults - the burning, stabbing after-pain that can outlast a shingles rash. That was the first approved pain signal, and it was a real one. Randomised trials later used titration toward 1800 mg a day. The 600 mg tablet suddenly had a pain story that was not a sales slide. How strong that story is, and where it thins, is the job of the 600 mg reviews article.
A separate product, gabapentin enacarbil, arrived in 2011 as Horizant for moderate-to-severe primary restless legs, with a PHN add in 2012. It is a prodrug with different absorption and it is not interchangeable with a Neurontin 600 mg tablet. Gralise, a once-daily gastroretentive gabapentin for PHN, is another non-swap. Same INN in conversation. Different labels on the desk.
The 2004 flag: promotion, not a poison verdict
Doctors may prescribe off-label. A company may not market off-label. That line is the whole case. Crossing it is a promotion crime, not a proof that the molecule fails its real uses.
David Franklin, a Parke-Davis medical liaison, filed a False Claims Act suit in 1996. He described paid talks, ghostwritten papers, and a push into bipolar disorder, migraine, general pain, and other uses the 1993 licence never named. On 13 May 2004 the Department of Justice announced that Warner-Lambert would plead guilty and pay more than $430 million in criminal and civil resolutions. The criminal fine alone was $240 million. Franklin's relator share was reported at about $24.6 million.
The government's own recap is still the cleanest primary: the 13 May 2004 DOJ release. It restates the December 1993 add-on limit in plain English. Court papers from that era also put a hard number on the drift: more than three-quarters of Neurontin prescriptions in 2000 were already written for unapproved uses. That is a volume signal, not an efficacy signal.
Keep the two files separate. The scandal is how the drug was sold. The pharmacology of the 600 mg tablet is how the drug works when the indication is real. Confusing them is how a useful add-on gets thrown out with the marketing. The titration and kidney rules that actually keep people safe are in the eGFR and taper guide.
What this desk posts after the noise
Post the small honest version. Gabapentin is an Ann Arbor add-on that later earned a shingles-nerve indication. The 600 mg scored tablet is a 1998 unit that still dominates cheap-generic searches. The GABA name is a fossil. The 2004 case is a teaching file on promotion. None of that makes the molecule a mood drug, a back-pain drug, or a sleep tonic.
Read the label narrowly and the history gets quieter. The loud years were a marketing amplifier on a modest licence. The tablet that survived is still a 600 mg scored film-coat with a calcium-channel job. If a thread treats Neurontin as a general calm pill, flag it. If a clinician is adding it to a seizure stack or titrating it for postherpetic neuralgia, the original Ann Arbor brief still holds.
Reader mail
Reader questions on this article
Answered by Dr. Nathan Whitfield, MD · Internal medicine & clinical pharmacology
Readers pinged the desk after this history post. These are the flags worth answering in full.
Because names freeze at launch. Chemists wanted a brain-penetrant GABA analogue, fused a fatty ring onto GABA, and named the hybrid after the parent. The hybrid never sat on GABA receptors. The later lock is the alpha-2-delta subunit on calcium channels. By the time that was clear, Neurontin was already on shelves and in seizure add-on notes. Companies do not rename a marketed anticonvulsant to fix a textbook. So the name is a fossil ping. I still write the subunit on the first line of a consult so nobody reasons from the badge. The labelled strengths, including the 600 mg scored tablet, are in the Neurontin 600 mg monograph.
Was Ann Arbor really the lab, or is that just a brand story?
Ann Arbor is the real bench, not a slogan. Parke-Davis, then under Warner-Lambert, developed gabapentin there. Later FDA correspondence still lists Parke-Davis at Plymouth Road in Ann Arbor. European use came first; the US add-on licence landed in December 1993. When people say 'Pfizer invented Neurontin' they are collapsing the timeline. Pfizer bought Warner-Lambert in June 2000 and inherited the brand, the 600 mg tablet line, and the off-label volume. The chemistry and the first licence are an Ann Arbor / Parke-Davis file.
Can I just order cheap generic 600 mg gabapentin online without a prescription?
This desk will not walk you to a cart. A 600 mg tablet is a labelled US strength, and generic gabapentin is often cheap, but cheap is not a licence to skip a clinician. The 1998 scored tablet can be split, and halves have a 28-day discard clock. Day 1 of the postherpetic-neuralgia ladder is still 300 mg, not a cold 600 mg swallow. Kidneys clear every milligram unchanged, so an online bottle with no eGFR is a bad start. Educational only - take the prescription question to the person who can see your seizure history, pain type, and creatinine.
I thought 1993 already covered nerve pain. Did it?
No. December 1993 was adjunctive partial seizures in adults. Adjunctive means add-on, not solo. The first approved pain indication was postherpetic neuralgia in 2002, nine years later. Everything you heard in the 1990s about bipolar illness, migraine prevention, or general aching sat outside that first licence. Doctors can still choose an off-label use on their own judgment. A company cannot market those uses. That distinction is the spine of the 2004 case. If your 600 mg tablet is for shingles-nerve pain, you are on the later, labelled flag. If it is for a mood or back-pain story, you are in the noise the marketing years amplified.
What exactly did Warner-Lambert pay for in 2004?
Promotion, not a finding that the tablet is poison. On 13 May 2004 the Department of Justice said Warner-Lambert would plead guilty and pay more than $430 million in criminal and civil resolutions over off-label Neurontin promotion. The criminal fine was $240 million. David Franklin, the medical liaison who filed the 1996 whistleblower suit, received about $24.6 million of the civil recovery. Paid talks and ghostwritten articles were part of the alleged machine. The DOJ recap is still up as a May 2004 press release. I keep that file next to the label, not instead of it.
Does the brand Neurontin still matter if my bottle says gabapentin 600 mg?
Clinically the INN is the molecule. Generic 600 mg gabapentin is the same active drug as a Neurontin 600 mg tablet when the product is an immediate-release scored tablet. The brand name matters for history, for old prescriptions, and for not mixing products. Horizant is gabapentin enacarbil, a prodrug approved in 2011 for restless legs, with PHN in 2012. Gralise is a once-daily PHN gabapentin that is not interchangeable with Neurontin. If your bag says 600 mg gabapentin tablet, you are in the immediate-release family this post is about. If it says Horizant or Gralise, you are holding a different labelled object.
Should the lawsuit make me refuse gabapentin for shingles pain?
I would not refuse a labelled use because of a marketing case. Postherpetic neuralgia is on the US label. The 2004 settlement was about how unapproved uses were pushed, not about wiping the 2002 pain indication. What the case should sharpen is skepticism when a 600 mg tablet is handed over for ordinary backache or 'just to calm you down.' Those were the loud years. For after-shingles nerve pain, the honest question is titration and kidneys, not brand guilt. If the tablet is not helping after a proper climb, that is a clinical conversation, not a courtroom one.
Is gabapentin enacarbil just a newer Neurontin 600 mg?
No, and swapping them is a common miss. Horizant is gabapentin enacarbil, approved 6 April 2011 for moderate-to-severe primary restless legs in adults, then for PHN in 2012. It uses different gut transporters, is taken with food, and must be swallowed whole. A scored Neurontin 600 mg tablet is immediate-release gabapentin with saturable LAT1 absorption. Same family in a lecture. Different labels, different schedules, different 'do not crush' rules. If someone tells you to substitute a 600 mg generic for Horizant to save money, flag it. Ask the prescriber for a product-specific plan.
Who should I believe - old forum posts or the 1993 licence?
Believe the licence for what the company was allowed to claim, and believe trials for what the drug can do. Forum volume is not a third licence. In 2000, court papers put more than 78 percent of Neurontin prescriptions on unapproved uses. That is how a quiet Ann Arbor add-on became a cultural pain signal. I still start with December 1993 and 2002, then ask what the person's actual diagnosis is. A readable patient page is at MedlinePlus. For the milligram grid and the kidney line, use the cheap 600 mg start and eGFR note rather than a thread.
General education from a clinician, not personal medical advice. Bring your own history to your own prescriber.
Last Updated